Corporate Profile

Sensei is a clinical-stage immunotherapy company committed to the discovery and development of next-generation therapies for the treatment of cancer. Its proprietary ImmunoPhage platform, leveraging the self-adjuvanted and highly immunogenic properties of engineered bacteriophage, allows Sensei to develop novel therapeutics that target key mechanisms of checkpoint resistance to induce a robust, focused and coordinated immune response.

Sensei is developing a library of ImmunoPhage targeting multiple tumor-associated antigens utilizing its proprietary platform and GMP manufacturing facility to treat patients using a personalized, yet off the shelf cocktail approach.

Sensei’s pipeline includes its lead product candidate, SNS-301, which is currently being evaluated in combination with the PD-1 inhibitor, pembrolizumab, for the treatment of squamous cell carcinoma of the head and neck.

Additional preclinical programs include SNS-401 for the treatment of Merkel cell carcinoma and a human monoclonal antibody program targeting the immune checkpoint VISTA, or V-set immunoglobulin domain suppressor of T cell activation.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Presentation

News Releases

Sensei Biotherapeutics Announces Closing of Initial Public Offering

BOSTON and ROCKVILLE, Md. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the closing of its initial public offering of 7,000,052 shares of

Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON and ROCKVILLE, Md. , Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052

Sensei Biotherapeutics Announces Launch of Initial Public Offering

BOSTON, MA    and ROCKVILLE, MD  –  February 1, 2021  – Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has launched an underwritten initial public offering of 5,885,000

Events

More events are coming soon.